Biotechnology company Moderna (MRNA) has delivered strong stock performance this year, having more than doubled as of the time of writing. The company is approaching a key regulatory decision point, and the market is closely watching its next moves.
Moderna has been advancing the development of its influenza vaccine candidate, mRNA-1010, and submitted a regulatory application earlier this year. The U.S. Food and Drug Administration (FDA) is expected to issue an approval or rejection decision on the vaccine by August 5. This date is crucial for Moderna, because securing approval in the flu space could help the company establish a leading position in that market. Although multiple flu vaccines are already available, their effectiveness is generally not remarkable, with U.S. efficacy rates typically ranging between 40 percent and 60 percent. In Phase 3 clinical trials, mRNA-1010 demonstrated superior performance compared to licensed vaccines in patients aged 50 and older, an age group that generally faces higher risks of severe illness, hospitalization, and death.
Recent developments have further increased the likelihood of approval. An advisory committee convened by the FDA voted on whether mRNA-1010 should receive approval, and the result was unanimous in favor. While the FDA does not always follow the advice of these experts, it typically does so. Therefore, a failure to approve mRNA-1010 would surprise the market.
After the advisory committee expressed confidence in mRNA-1010, Moderna’s stock price rose. This suggests that the market may have already priced in a positive outcome to some extent, and the stock may not react dramatically when the vaccine is officially approved. Even so, there are still ample reasons to invest in Moderna. The company has once again demonstrated its innovative capabilities with mRNA-1010, just as it previously did with its COVID-19 vaccine, which became a leader in that field.
The overall flu vaccine market is relatively limited in size. It was estimated at $8.9 billion last year, although it is expected to maintain solid growth over the next several years. Potential sales from this segment alone are not sufficient to support Moderna’s current market capitalization of approximately $24.5 billion, especially given that revenue from its already approved products is comparatively modest.
However, the company boasts a rich R&D pipeline, with multiple candidates poised to become key growth drivers. For example, Moderna is developing mRNA-4157, an investigational personalized cancer vaccine that has shown encouraging clinical trial results and is currently in multiple Phase 2 and Phase 3 studies. In addition, the company is tackling more challenging targets, such as developing an HIV vaccine. Success in the flu vaccine market will help Moderna advance into more profitable market areas. Over the next five years, the company is expected to have a broader portfolio of approved products while generating substantial revenue and earnings.
In summary, although Moderna’s stock price has doubled this year, the positive momentum in its flu vaccine approval process, its rich late-stage pipeline, and its strategic positioning in broader markets all underpin its long-term investment value. The near-term stock price may have already reflected expectations for flu vaccine approval, but the company’s future growth potential depends more on breakthrough progress in innovative areas such as cancer vaccines and HIV vaccines.
